Clinical effects of N-acetylcysteine in the treatment of acute decompensated heart failure

Randomised blinded control pilot trial investigating the effect of N-acetylcysteine in the treatment of acute decompensated heart failure

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000766910

Enrollment

Registered

2011-07-21

Start date

2011-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Heart failure is a condition cause by heart muscle weakness. As a result the circulation to the body becomes inefficient and blood flow tends to fall. We are studying whether a simple medicine which is used in other settings can improve blood flow and thus outcomes for patients admitted to hospital with heart failure.

Interventions

Oral N-acetylcysteine - 600mg twice daily for 5 days initiated within 24 hours of admission for acute decompensated heart failure

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

-Hospital admission with acute decompensated HF including congestion (or) hypotension (or) worsening renal function (or) other end organ dysfunction. -NYHA Class III or IV -LVEF < 40%

Exclusion criteria

Age < 18, and >75 -LVAD or ECMO in situ or likely requirement for LVAD/ECMO within 24 hrs -endotracheal intubation/ventilation -cardiac or other solid organ transplantation -STEMI at presentation -Allergy to n-acetylcysteine - pregnancy

Outcome results